These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 9753313

  • 1. Myocardial infarction and stroke in young women: what is the impact of oral contraceptives?
    Lewis MA.
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S68-77. PubMed ID: 9753313
    [Abstract] [Full Text] [Related]

  • 2. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR, Ory H.
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [Abstract] [Full Text] [Related]

  • 3. Modern oral contraceptives and cardiovascular disease.
    Rosenberg L, Palmer JR, Sands MI, Grimes D, Bergman U, Daling J, Mills A.
    Am J Obstet Gynecol; 1997 Sep; 177(3):707-15. PubMed ID: 9322646
    [Abstract] [Full Text] [Related]

  • 4. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
    Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R.
    Contraception; 1997 Sep; 56(3):129-40. PubMed ID: 9347202
    [Abstract] [Full Text] [Related]

  • 5. Bias versus causality: interpreting recent evidence of oral contraceptive studies.
    Spitzer WO.
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S43-50. PubMed ID: 9753310
    [Abstract] [Full Text] [Related]

  • 6. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
    Farmer RD, Lawrenson RA.
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
    [Abstract] [Full Text] [Related]

  • 7. Thrombotic diseases in young women and the influence of oral contraceptives.
    Lidegaard O.
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S62-7. PubMed ID: 9753312
    [Abstract] [Full Text] [Related]

  • 8. Smoking and use of oral contraceptives: impact on thrombotic diseases.
    Lidegaard O.
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
    [Abstract] [Full Text] [Related]

  • 9. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR.
    Lancet; 1997 Jan 11; 349(9045):83-8. PubMed ID: 8996419
    [Abstract] [Full Text] [Related]

  • 10. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G, Kohlmeier L, Brenner H.
    Eur J Clin Nutr; 1998 Oct 11; 52(10):711-5. PubMed ID: 9805216
    [Abstract] [Full Text] [Related]

  • 11. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.
    Schwingl PJ, Shelton J.
    Contraception; 1997 Mar 11; 55(3):125-9. PubMed ID: 9114999
    [Abstract] [Full Text] [Related]

  • 12. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
    Winkler UH.
    Am J Obstet Gynecol; 1998 Sep 11; 179(3 Pt 2):S51-61. PubMed ID: 9753311
    [Abstract] [Full Text] [Related]

  • 13. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B.
    Ann Pharmacother; 1995 Sep 11; 29(7-8):736-42. PubMed ID: 8520092
    [Abstract] [Full Text] [Related]

  • 14. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from International Study on Oral Contraceptives and Health of Young Women.
    Heinemann LA, Lewis MA, Thorogood M, Spitzer WO, Guggenmoos-Holzmann I, Bruppacher R.
    BMJ; 1997 Dec 06; 315(7121):1502-4. PubMed ID: 9420491
    [Abstract] [Full Text] [Related]

  • 15. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study.
    Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ.
    Contraception; 1998 Feb 06; 57(2):67-70. PubMed ID: 9589831
    [Abstract] [Full Text] [Related]

  • 16. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C.
    Lancet; 1995 Dec 16; 346(8990):1589-93. PubMed ID: 7500750
    [Abstract] [Full Text] [Related]

  • 17. Hormonal contraception: benefits versus risks.
    Goldzieher JW.
    Am J Obstet Gynecol; 1987 Oct 16; 157(4 Pt 2):1023-8. PubMed ID: 3674179
    [Abstract] [Full Text] [Related]

  • 18. Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?
    Contracept Rep; 1996 Apr 16; 7(1):3-6. PubMed ID: 12320047
    [Abstract] [Full Text] [Related]

  • 19. An epidemiologic survey of cardiovascular disease in women taking oral contraceptives.
    Thorogood M, Vessey MP.
    Am J Obstet Gynecol; 1990 Jul 16; 163(1 Pt 2):274-81. PubMed ID: 2196799
    [Abstract] [Full Text] [Related]

  • 20. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP.
    Lancet; 1995 Dec 16; 346(8990):1593-6. PubMed ID: 7500751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.